<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-06-28">June 28, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Claudia</forename><surname>Brandt</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Pneumology and Immunology</orgName>
								<orgName type="institution">Cystic Fibrosis Center / Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anja</forename><surname>Thronicke</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Pneumology and Immunology</orgName>
								<orgName type="institution">Cystic Fibrosis Center / Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jobst</forename><forename type="middle">F</forename><surname>Roehmel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Pneumology and Immunology</orgName>
								<orgName type="institution">Cystic Fibrosis Center / Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><surname>Krannich</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Biostatistics Unit</orgName>
								<orgName type="institution" key="instit1">Berlin Institute of Health</orgName>
								<orgName type="institution" key="instit2">Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Doris</forename><surname>Staab</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Pneumology and Immunology</orgName>
								<orgName type="institution">Cystic Fibrosis Center / Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Carsten</forename><surname>Schwarz</surname></persName>
							<email>carsten.schwarz@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Pediatric Pneumology and Immunology</orgName>
								<orgName type="institution">Cystic Fibrosis Center / Charité -Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Augustenburger Platz 1</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">University of Pittsburgh</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution">UNITED STATES</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-06-28">June 28, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">92AAD18E11FCD80B4C70D1ABF4854A9B</idno>
					<idno type="DOI">10.1371/journal.pone.0158193</idno>
					<note type="submission">Received: February 17, 2016 Accepted: June 13, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:27+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>70% predicted: treated: +0.5±4.7%</term>
					<term>control: -4.0 ±6.3%</term>
					<term>p = 0.0132</term>
					<term>FEV1 50-69% predicted: treated: -0.5±4.4%</term>
					<term>control: -0.8±3.8%</term>
					<term>p = 0.7142</term>
					<term>FEV1 49% predicted: treated: -0.6±3.4%</term>
					<term>control: -2.4±4.8%</term>
					<term>p = 0.0898) CF, Cystic Fibrosis</term>
					<term>FEV1, forced expiratory volume in 1 s</term>
					<term>COPD, chronic obstructive pulmonary disease</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Chronic lung disease is the leading cause of death in patients with Cystic Fibrosis (CF) and is often treated with bronchodilators.</s><s>It is not known whether long-term tiotropium bromide treatment may have a positive impact on lung function.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>This retrospective cohort study estimated annual lung function decline utilizing longitudinal data for forced expiratory volume in 1 s (FEV1).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>A total of 160 adult patients with CF were analyzed.</s><s>The subjects treated for 24 months with tiotropium bromide had a significantly slower decline of mean annual change of FEV1 (treated: -0.3±4.0%;</s><s>control: -2.3±5.0%;</s><s>p = 0.0130).</s><s>In patients with FEV1 70% predicted, long-term tiotropium bromide treatment was associated with greater improvements in annual lung function decline (FEV1</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Cystic Fibrosis (CF) is a life-limiting autosomal recessive disorder that affects more than 70,000 individuals worldwide <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>.</s><s>Chronic airway infection, bronchiectasis, hypoxemia and hypercapnia as well as defective mucociliary clearance and bronchial and mucus obstruction are key features of the CF respiratory disease, resulting in a progressive lung function decline.</s><s>Pulmonary insufficiency, with extensive airway destruction, is the main cause of death for patients with CF <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref>.</s><s>To describe disease severity and to monitor lung function in CF, the forced expiratory volume in 1 s (FEV1) is commonly used.</s><s>FEV1 represents a marker of disease progression and a predictor of survival for patients with CF <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref>.</s><s>To improve pulmonary function and lessen wheezing <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b10">11]</ref> inhaled short-or long-acting bronchodilators have been routinely used in standard pulmonary CF therapy <ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref> but until now there is no approved indication for CF <ref type="bibr" target="#b11">[12,</ref><ref type="bibr" target="#b14">15]</ref>.</s><s>The long-acting, inhaled anticholinergic bronchodilator tiotropium bromide (hereafter referred to as tiotropium) is approved for maintenance therapy in patients with chronic obstructive pulmonary disease (COPD) <ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref>.</s><s>Several studies investigated the efficacy of tiotropium in patients with COPD.</s><s>During 12 months of tiotropium treatment, improvements in lung function and measures of exacerbations were observed in patients with COPD <ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref>.</s></p><p><s>With regard to CF, safety and efficacy of inhaled tiotropium were investigated in children and adults with CF in three randomized placebo-controlled multicenter trials with tiotropium treatment durations of 12 weeks <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b23">24]</ref>.</s><s>Dosages of 2.5 and 5 μg inhaled tiotropium showed consistent improvement in lung function <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref>.</s><s>However, statistically significant differences in the measure of lung function were only reached in one study.</s><s>Furthermore, the improvement in lung function was greater in patients who received the higher dose of 5 μg tiotropium <ref type="bibr" target="#b23">[24]</ref>.</s><s>Until now, long-term effects in CF as well as tiotropium dosages of 18 μg have not been studied.</s><s>It is not known whether long-term tiotropium treatment may reduce lung function decline.</s></p><p><s>Here, longitudinal data of long-term 18 μg once daily inhaled tiotropium treatment in adult patients with different CF disease severities is presented.</s><s>We hypothesized that long-term treatment with tiotropium for 24 months is effective in reducing lung function decline compared to non-tiotropium based CF standard therapy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>This was a retrospective cohort study of individuals with documented CF followed at the Cystic Fibrosis Center at the Charité-Universitätsmedizin Berlin (Berlin, Germany) from 2004 to 2014.</s><s>Data were extracted from the patient registry database MUKO.doc (Axaris software and systeme GmbH, Ulm, Germany).</s><s>Routinely collected longitudinal data on lung function and measures of exacerbation were available for 160 adults with confirmed diagnosis of CF <ref type="bibr" target="#b25">[26]</ref>.</s><s>Study protocol was approved by the local ethics committee of the Charité-Universitätsmedizin Berlin (EA2/117/14).</s><s>All participants involved in this study provided written informed consents.</s></p><p><s>In this retrospective cohort study longitudinal data were used to evaluate modulatory effects of inhaled bronchodilator tiotropium (18 μg once daily) on pulmonary lung function and measures of exacerbation for 24 months.</s><s>The primary endpoint was the mean annual decline of FEV1 during long-term tiotropium therapy compared to non-tiotropium treated control patients.</s><s>The secondary endpoint included mean annual change of exacerbations.</s><s>Pulmonary exacerbations were defined using criteria provided by Bilton et al. <ref type="bibr" target="#b26">[27]</ref>.</s><s>Patients with pulmonary exacerbations showed a recent change in at least two of the following parameters: change in sputum volume or color, increased cough, increased malaise, fatigue or lethargy, anorexia or weight loss, decrease in pulmonary function by 10% or more / radiographic changes and increased dyspnea <ref type="bibr" target="#b26">[27]</ref>.</s><s>In order to minimize bias and confounding, a matching procedure on potential confounders was performed.</s><s>Appropriate controls for interpatient comparison were identified with regard to: pre-bronchodilator baseline lung function (FEV1 0M ± 5%; FEV1 0M defined as baseline FEV1 at the beginning (month 0) of 24 months observation period and before tiotropium treated patients started their tiotropium add-on therapy), age (± 5 years), gender, BMI, baseline concomitant medication and Pseudomonas aeruginosa colonization (Table <ref type="table" target="#tab_0">1</ref>, for demographic and baseline characteristics of the subgroups please see S1-S3 Tables).</s><s>Baseline FEV1 (FEV1 0M / month 0) was defined as last measured FEV1 immediately before subjects started their tiotropium inhalation therapy.</s><s>Follow-up FEV1 for 12 and 24 months were defined as mean of FEV1 between baseline/0 month to 12 months of observation period (month 12) as well as 12 to 24 months of observation period (month 24).</s><s>All clinical parameters were determined at each patient visit or hospitalization and were recorded in our local patient registry.</s></p><p><s>The index date, for patients treated with tiotropium, was defined as date of tiotropium prescription.</s><s>The index date indicated the last patient visit before first tiotropium intake.</s><s>Baseline characteristics, including FEV1 0M as a matching variable, were determined at the index date.</s><s>The 80 selected controls were identified via matching variables (gender, age ± 5 years, FEV1 0M ± 5%).</s><s>The index date, for tiotropium untreated patients, was defined as date of first occurrence of the index event (FEV1 0M ± 5%, gender, age ± 5 years) during both the patient 0 s enrollment period and the analysis period (2004 to 2014).</s><s>The main outcome in this study was the mean annual change of FEV1 from index date until the end of a 24 month period of observation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study subjects</head><p><s>A total of 415 patients were recorded in our local patient registry from 2004 to 2014 and each of the eligibility criteria below was examined.</s><s>Inclusion criteria were: 18 years of age, patients have given written informed consent, patients with confirmed CF diagnosis, pulmonary lung function measures for a 24 months observation period and measures of exacerbation for 24 months.</s><s>Exclusion criteria were: patients after lung transplantation, patients that did not meet matching criteria and patients with &lt;5 FEV1 measures during observation period.</s><s>Finally, 160 patients, aged 18-61 years, were included in our study with 80 patients per group (tiotropium treated and tiotropium untreated).</s><s>The matching criteria were: gender, age ± 5 years and FEV1 0M ± 5%.</s><s>A number of 135 patients out of 415 patients with CF were treated with tiotropium and 280 patients out of 415 patients were never treated with tiotropium.</s><s>Due to our inclusion, exclusion and matching criteria 55 patients of 135 tiotropium treated patients were excluded and 200 patients of non-tiotropium treated 280 patients were excluded.</s><s>A matchedpair analysis comparing patients who underwent tiotropium treatment and those not treated with tiotropium was performed.</s><s>The matching ratio was 1:1.</s><s>All patients were grouped into three different disease severities on the basis of baseline FEV1/FEV1 0M at the beginning (month 0) of 24 months observation period and before tiotropium treated patients start their tiotropium add-on therapy.</s><s>The subgroup determination was similar to those reported elsewhere <ref type="bibr" target="#b9">[10]</ref>.</s><s>Pre-bronchodilator baseline FEV1 0M 70% predicted for a mild, FEV1 0M 50-69% predicted for a moderate and a moderately severe and FEV1 0M 49% predicted for a severe and a very severe degree of CF lung disease severity <ref type="bibr" target="#b9">[10]</ref>.</s><s>Tiotropium was used as add-on to standard CF treatment.</s><s>Patients received 18 μg of tiotropium once daily, delivered through the HandiHaler powder formulation inhalation device (Boehringer Ingelheim, Germany).</s><s>All patients were able to inhale tiotropium and they were routinely educated in inhalation technique.</s><s>Compliance was reviewed and documented at each visit.</s><s>All patients proceeded to receive their standard-of-care therapy during the observed time period.</s><s>The concomitant use of pulmonary medication, using short-and long-acting β-agonists as well as short acting anticholinergic drugs, was allowed.</s><s>The number of study subjects treated with β-agonists and/or glucocorticoids and inhaled antibiotics did not differ between the groups (Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>In this retrospective cohort study, 415 patients with CF were screened.</s><s>Due to eligibility criteria 160 patients with CF were included.</s><s>The matching ratio was 1:1, in which pairs of tiotropium treated and tiotropium untreated subjects were formed.</s><s>To estimate an adequate sample size we focused on the FEV1 change between groups.</s><s>A mean change of -1.44 in the control group and a mean change of 0.78 in the tiotropium group for FEV1 were estimated <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref>.</s><s>By assuming a common standard deviation of 4.8 for both groups, an effect size of 0.46 was calculated <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref>.</s><s>A two-sided t-test and a sample size of 80 per group lead to a Power of 82% <ref type="bibr" target="#b30">[31]</ref>.</s><s>We applied an alpha of 0.05.</s><s>Results were presented as means ± standard deviations (SD) or median and interquartile range (IQR) as appropriate, unless otherwise stated.</s><s>The characteristics of tiotropium treated patients versus non-tiotropium treated control patients were compared, using non-parametric, non-paired Mann-Whitney U or t-test depending on scale and distribution.</s><s>For comparison of different severity groups, FEV1 0M : 70%, 50-69% and 49%, of control and tiotropium groups, the Kruskal-Wallis test was used.</s><s>Furthermore, mean annual change of FEV1 was adjusted for confounding using multiple linear regression.</s></p><p><s>GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA) was used to perform statistical analysis.</s><s>A p value &lt; 0.05 was considered statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cohort characteristics</head><p><s>This retrospective cohort analysis included longitudinal data of 160 patients with CF, registered in MUKO.doc database from February 2004 until July 2014.</s><s>Patients with less than 24 months tiotropium treatment were excluded (Fig <ref type="figure" target="#fig_0">1</ref>).</s><s>Two cases of a dry mouth symptom, typically associated with anticholinergics were reported in the tiotropium treated group but did not lead to discontinuation of treatment.</s></p><p><s>The demographic data, mean age and baseline pulmonary function (FEV1 0M ) were comparable across the study groups and are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s><s>Furthermore, the multiple linear regression showed only a significant influence of the tiotropium medication with an estimate beta of 1.9 (SE = 0.7) and p = 0.008.</s><s>All confounding factors (Table <ref type="table" target="#tab_0">1</ref>) including baseline FEV1 0M remained without significant</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Annual change of lung function</head><p><s>There was a significant difference between non-tiotropium treated control (n = 80; -2.</s><s><ref type="table" target="#tab_1">2</ref>).</s><s>The demographic data and baseline characteristics were comparable across the tiotropium treated and non-tiotropium treated control subgroups with baseline FEV1 0M 70% and are summarized in S1 Table.</s></p><p><s>Tiotropium treated patients with FEV1 0M lower than 70% indicated smaller amounts but not statistically significant for annual lung function decline compared to untreated control patients.</s><s><ref type="table" target="#tab_1">2</ref>).</s><s>Baseline characteristics were comparable across tiotropium untreated and tiotropium treated patients with baseline FEV1 0M 50-69% and are summarized in S2 Table <ref type="table">.</ref></s><s>A similar observation for mean change of lung function per year (p.a.) was noted in patients with a severe and very severe degree of severity, i.e. 49% baseline FEV1 0M values (control: n = 39; -2.4 ± 4.8% p.a.; tiotropium: n = 39; -0.6 ± 3.4% p.a.; p = 0.0898; Fig <ref type="figure" target="#fig_2">2</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>and Table 2; please see S3 Table for baseline characteristics).</head><p><s>The rate of lung function decline for different disease severities on 12 and 24 months of observation period are shown in Fig 2C <ref type="figure">.</ref></s><s>Patients with FEV1 0M 70% and 49% without tiotropium therapy had continuous lower FEV1 values compared to baseline and to tiotropium treated study group.</s><s>In the subgroup of patients with a moderate and moderately severe degree of severity (FEV1 0M 50-69%), there were comparable lung functions for untreated and treated patients until 12 months of observation period.</s><s>After &gt;12 months of treatment, the tiotropium group showed slightly higher FEV1 values compared to untreated controls.</s><s>Furthermore, tiotropium treatment resulted in continuous higher FEV1 values compared to baseline for patients with CF with FEV1 0M 70%.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pulmonary Exacerbations</head><p><s>There was no statistical difference between tiotropium and untreated study group for mean annual change of exacerbations (control: n = 80; +0.2 ± 1.7% p.a.; tiotropium: n = 80; +0.1 ± 1.9% p.a.; p = 0.6482; Table <ref type="table" target="#tab_1">2</ref>).</s><s>Regarding different disease severities, FEV1 0M 70%, 50-69% and 49% are shown in Table <ref type="table" target="#tab_1">2</ref>. Tiotropium treatment was not associated with changes in mean annual change of exacerbation in the observed study cohort.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In the presented retrospective cohort study, for the first time, data on long-term tiotropium therapy (24 months, 18 μg) used in the pulmonary treatment of adult patients with CF are provided.</s><s>The results suggest a reduced decline rate for mean annual change of FEV1, without influencing mean annual change of exacerbation in adult patients with CF.</s><s>As compared with findings of a previous phase II trial in patients with CF <ref type="bibr" target="#b23">[24]</ref>, the results shown here (mean change of FEV1 percent predicted: control: -2.3 ± 5.0% p.a.; n = 80; tiotropium: -0.3 ± 4.0% p.a.; n = 80; p = 0.0130; Fig <ref type="figure" target="#fig_2">2A</ref>) support that once-daily inhaled tiotropium reduces rates of lung function decline statistically significant.</s><s>With regard to existing data focused on bronchodilator utilization in COPD patients, it is known that tiotropium treatment ( 12 months) is effective in improving lung function <ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref>.</s><s>The mean rate of FEV1 decline in our control cohort was similar to those reported elsewhere <ref type="bibr" target="#b31">[32]</ref>.</s><s>In contrast, results of a phase III trial with 12 weeks of tiotropium treatment in CF <ref type="bibr" target="#b24">[25]</ref> could not confirm statistically significant improvements in lung function induced by tiotropium.</s><s>The observed period of 12 weeks tiotropium treatment <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref> reflects a smaller time period and may not adequately monitor long-term modulatory effects of tiotropium treatment in CF.</s><s>Tashkin and coworkers claimed that short-term bronchodilator response was not an adequate criterion to predict long-term outcome of FEV1 course <ref type="bibr" target="#b18">[19]</ref>.</s><s>According to this, tiotropium therapy duration seemed to be crucial for therapy success.</s><s>In our study, a higher dosage of 18 μg tiotropium has been applied, instead of 2.5 and 5 μg tiotropium used in former studies <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b24">25]</ref>.</s><s>The improvement in lung function was larger with higher tiotropium dosages <ref type="bibr" target="#b23">[24]</ref>.</s><s>Similar to our results, studies among patients with COPD, dosages of 18 μg tiotropium resulted in reduced lung function decline <ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref>.</s><s>Beside tiotropium dosage other factors, such as selection of certain patient groups (e.g.</s><s>age) and study design could also account for differences.</s></p><p><s>We provide long-term tiotropium information on different FEV1 groups at baseline.</s><s>Tiotropium treatment seemed to be most effective in patients with a mild degree of CF disease severity: FEV1 0M 70% (Fig 2B <ref type="figure" target="#fig_2">and 2C</ref>).</s><s>Based on this finding, we hypothesized that, patients with lower FEV1 0M values had advanced airway destruction and fixed obstruction, resulting in partly restricted admission of inhaled tiotropium.</s><s>Pulmonary exacerbations are promoted by inflammation and negatively influenced mucociliary clearance, which contribute to a worsening airway obstruction, a decline in lung function, and a profound negative impact on perceived quality of life <ref type="bibr" target="#b1">[2]</ref>.</s><s>As pulmonary exacerbations have very severe consequences in CF, both in terms of current morbidity as well as implications for long-term morbidity and mortality, the reduction of exacerbation risk is one goal of CF treatment <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b32">33]</ref>.</s><s>Here, tiotropium treatment was not associated with modifications in mean change of exacerbation.</s><s>Related findings have been reported elsewhere <ref type="bibr" target="#b24">[25]</ref>.</s><s>Since 2004, 135 of 415 patients with CF received tiotropium treatment in our center.</s><s>Eighty adult patients with CF have been treated with a long-term tiotropium therapy and were included in this study.</s><s>Tiotropium is well tolerated in patients with CF consistent with the known safety profile in COPD <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b33">34]</ref>.</s></p><p><s>This study provides data on the efficacy of long-term tiotropium treatment administered for 24 months to adult patients with a wide range of baseline FEV1 0M .</s><s>In order to minimize bias and confounding, a matching procedure on potential confounders was performed.</s><s>Limitations of this study include the relatively small number of patients as a consequence of CF being a rare disease, the susceptibility of the study design for confounding and bias, especially selection and observer bias.</s><s>Moreover, it should be taken into account, that this study was neither randomized nor placebo controlled due to the fact that all parameters in this study have been assessed retrospectively.</s><s>Another potential limitation relates to the complex standard CF medication regimes including multiple drugs and application intervals.</s></p><p><s>Further prospective and randomized long-term studies of tiotropium treatment in CF are necessary.</s><s>This study may represent a pilot study to evaluate possible parameters and procedures for further evaluations.</s><s>Patients with CF showed altered airway smooth muscle physiology resulting in airway smooth muscle contraction, airway narrowing and airway dysfunction <ref type="bibr" target="#b34">[35]</ref>.</s><s>We hypnotized that the pathophysiological reasons of clinical benefits with tiotropium are various: tiotropium is an anticholinergic agent, able to reduce basal airway smooth muscle tone, it has the potential to inhibit allergen-induced increases in airway smooth muscle thickening in animal models <ref type="bibr" target="#b35">[36]</ref> and in addition to its effect as a bronchodilator <ref type="bibr" target="#b36">[37]</ref> tiotropium might have an inhibitory effect on airway remodeling in various non-CF animal models <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b38">39]</ref>.</s><s>Furthermore, it was suggested that a prolonged duration of treatment with tiotropium was required for beneficial effect in animal models <ref type="bibr" target="#b38">[39]</ref>.</s><s>Airway epithelium damage and remodeling are fundamental elements of lung pathology progression in CF <ref type="bibr" target="#b39">[40]</ref>.</s><s>Therefore, long-term tiotropium could be an additional effective treatment option to relieve bronchoconstriction and to prevent airway remodeling in the future <ref type="bibr" target="#b38">[39]</ref>.</s></p><p><s>Continuative research is needed to elucidate the positive effects of long-term anti-obstructive tiotropium therapy, safety and tolerability in patients with CF and to identify differences between different CF patient groups, e.g.</s><s>disease severities.</s><s>The optimization of CF standard therapy regarding anti-obstructive therapy will be the objective for further studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting Information</head><note type="other">S1</note></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig 1 .</head><label>1</label><figDesc><div><p><s>Fig 1. Flow chart of patient selection for tiotropium treated and non-tiotropium treated control patient comparison.</s><s>All patients with confirmed CF diagnosis recorded in the MUKO.doc</s><s>database have given written informed consent.</s><s>doi:10.1371/journal.pone.0158193.g001</s></p></div></figDesc><graphic coords="5,57.83,78.01,518.12,351.84" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>3 ± 5.0% p.a.) and tiotropium treated study group (n = 80; -0.3 ± 4.0% p.a) in mean annual change of FEV1 percent predicted = 0.0130; Fig 2A and Table 2).</s><s>Particularly, tiotropium treated patients with FEV1 0M 70% showed significantly positive development of the mean annual change of FEV1 compared to untreated control patients (control: n = 19; -4.0 ± 6.3% p.a.; tiotropium: n = 19; +0.5 ± 4.7% p.a.; p = 0.0132; Fig 2B and Table</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig 2 .</head><label>2</label><figDesc><div><p><s>Fig 2. Annual change of FEV1.</s><s>Mean change of FEV1 (percent predicted) per year for (A) control (n = 80) and tiotropium treated study group (n = 80; p = 0.0130) and (B) for different disease severities: FEV1 0M 70% (n = 19; p = 0.0132), FEV1 0M 50-69% (n = 22), FEV1 0M 49% (n = 39).</s><s>(C) Normalized mean FEV1 values of tiotropium (n = 80) and non-tiotropium treated control patients (n = 80) and for different disease severities: FEV1 0M 70% (n = 19), FEV1 0M 50-69% (n = 22), FEV1 0M 49% (n = 39) on 0, 12 and 24 months observation period.</s><s>doi:10.1371/journal.pone.0158193.g002</s></p></div></figDesc><graphic coords="6,200.01,78.01,360.91,377.01" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Demographic and baseline characteristics of the study group.</s></p></div></figDesc><table><row><cell>Total</cell><cell>Control</cell><cell>Tiotropium 18 μg</cell><cell>p value</cell></row></table><note><p><s>Values expressed as mean ± standard deviation (SD) and number of patients (n) and proportion (%).</s><s>BMI: body mass index, FEV1: forced expiratory volume in 1 second, FEV1 0M : baseline FEV1 equates to begin (month 0) of observation period and before tiotropium treatment started.</s><s>doi:10.1371/journal.pone.0158193.t001</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Outcomes by allocation.</s></p></div></figDesc><table><row><cell>Control</cell><cell>Tiotropium 18 μg</cell><cell>p Value</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc><div><p><s>Table.</s><s>Demographic and baseline characteristics of the study group with FEV1 0M 70%.</s><s>(PDF) S2 Table.</s><s>Demographic and baseline characteristics of the study group with FEV1 0M 50-69%.</s><s>(PDF) S3 Table.</s><s>Demographic and baseline characteristics of the study group with FEV1 0M 49%.</s></p></div></figDesc><table><row><cell>(PDF)</cell></row><row><cell>S4 Table. Outcomes by allocation.</cell></row><row><cell>(PDF)</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS ONE | DOI:10.1371/journal.pone.0158193June 28, 2016  </note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We would like to thank all patients and all members of the Cystic Fibrosis Center Berlin for assistance and support.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Contributions</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cystic fibrosis genetics: from molecular understanding to clinical application</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Cutting</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrg3849</idno>
		<idno type="PMID">25404111</idno>
	</analytic>
	<monogr>
		<title level="j">Nature reviews Genetics</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="45" to="56" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Respiratory Care year in review 2012: invasive mechanical ventilation, noninvasive ventilation, and cystic fibrosis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Kallet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Volsko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Hess</surname></persName>
		</author>
		<idno type="DOI">10.4187/respcare.02412</idno>
		<idno type="PMID">23564873</idno>
	</analytic>
	<monogr>
		<title level="j">Respiratory care</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="702" to="711" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Cystic fibrosis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>O'sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Freedman</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(09)60327-5</idno>
		<idno type="PMID">19403164</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="issue">9678</biblScope>
			<biblScope unit="page" from="60327" to="60332" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Effectiveness of bronchodilators in cystic fibrosis. The American journal of medicine</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Cropp</surname></persName>
		</author>
		<idno type="PMID">8610713</idno>
		<imprint>
			<date type="published" when="1996">1996</date>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="19S" to="29S" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main">Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. The European respiratory journal</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kerem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Viviani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zolin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Macneill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hatziagorou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ellemunter</surname></persName>
		</author>
		<idno type="DOI">10.1183/09031936.00166412</idno>
		<idno type="PMID">23598952</idno>
		<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="125" to="133" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Airway remodelling and its relationship to inflammation in cystic fibrosis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Regamey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Jeffery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alton</forename><forename type="middle">Ew</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename></persName>
		</author>
		<idno type="DOI">10.1136/thx.2009.134106</idno>
		<idno type="PMID">20889525</idno>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="624" to="629" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Cystic fibrosis: pathogenesis and future treatment strategies</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Ratjen</surname></persName>
		</author>
		<idno type="PMID">19393104</idno>
	</analytic>
	<monogr>
		<title level="j">Respiratory care</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="595" to="605" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Taylor-Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Whitehead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Diderichsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">V</forename><surname>Olesen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pressler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Smyth</surname></persName>
		</author>
		<idno type="DOI">10.1136/thoraxjnl-2011-200953</idno>
		<idno type="PMID">22555277</idno>
	</analytic>
	<monogr>
		<title level="j">Thorax</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="860" to="866" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">Global Lung Function Initiative equations improve interpretation of FEV1 decline among patients with cystic fibrosis. The European respiratory journal</title>
		<author>
			<persName><forename type="first">S</forename><surname>Stanojevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mcdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Stocks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aurora</forename><forename type="middle">P</forename><surname>Prasad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<idno type="DOI">10.1183/09031936.00187314</idno>
		<idno type="PMID">25837028</idno>
		<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="262" to="264" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">Interpretative strategies for lung function tests. The European respiratory journal</title>
		<author>
			<persName><forename type="first">R</forename><surname>Pellegrino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Viegi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Brusasco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Crapo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Burgos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Casaburi</surname></persName>
		</author>
		<idno type="PMID">16264058</idno>
		<imprint>
			<date type="published" when="2005">2005</date>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="948" to="968" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">Inhaled bronchodilators for cystic fibrosis. The Cochrane database of systematic reviews</title>
		<author>
			<persName><forename type="first">C</forename><surname>Halfhide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Couriel</surname></persName>
		</author>
		<idno type="PMID">16235319</idno>
		<imprint>
			<date type="published" when="2005">2005</date>
			<biblScope unit="page">D003428</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">Long-acting bronchodilators in cystic fibrosis. Current opinion in pulmonary medicine</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Colombo</surname></persName>
		</author>
		<idno type="PMID">14534403</idno>
		<imprint>
			<date type="published" when="2003">2003</date>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="504" to="508" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Konstan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Butler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">V</forename><surname>Schidlow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Julius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<idno type="PMID">10497373</idno>
	</analytic>
	<monogr>
		<title level="j">Pediatric pulmonology</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="248" to="254" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Efficacy and adverse effects of drugs used to treat adult cystic fibrosis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Chopra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Manickam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Aronow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Maguire</surname></persName>
		</author>
		<idno type="DOI">10.1517/14740338.2015.994503</idno>
		<idno type="PMID">25604518</idno>
	</analytic>
	<monogr>
		<title level="j">Expert opinion on drug safety</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="401" to="411" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Factors influencing outcomes in cystic fibrosis: a center-based analysis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Butler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Konstan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Wohl</surname></persName>
		</author>
		<idno type="PMID">12527598</idno>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="20" to="27" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. International journal of chronic obstructive pulmonary disease</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bateman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Disse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Towse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Massey</surname></persName>
		</author>
		<idno type="PMID">20714373</idno>
		<imprint>
			<date type="published" when="2010">2010</date>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="197" to="208" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Pooled analysis of tiotropium Respimat((R)) pharmacokinetics in cystic fibrosis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Geller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moroni-Zentgraf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kattenbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Boland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pulmonary pharmacology &amp; therapeutics</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="217" to="223" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Ferguson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Flezar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Korn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Korducki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gronke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Abrahams</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12325-015-0218-0</idno>
		<idno type="PMID">26112656</idno>
	</analytic>
	<monogr>
		<title level="j">Advances in therapy</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="523" to="536" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses</title>
		<author>
			<persName><forename type="first">D</forename><surname>Tashkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kesten</surname></persName>
		</author>
		<idno type="PMID">12740259</idno>
	</analytic>
	<monogr>
		<title level="j">Chest</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1441" to="1449" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title level="m" type="main">Improved health outcomes in patients with COPD during 1 yr&apos;s treatment with tiotropium. The European respiratory journal</title>
		<author>
			<persName><forename type="first">W</forename><surname>Vincken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Van Noord</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Greefhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Bantje</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kesten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Korducki</surname></persName>
		</author>
		<idno type="PMID">11871363</idno>
		<imprint>
			<date type="published" when="2002">2002</date>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="209" to="216" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">A 4-year trial of tiotropium in chronic obstructive pulmonary disease</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Tashkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Celli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Senn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Burkhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kesten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Menjoge</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa0805800</idno>
		<idno type="PMID">18836213</idno>
	</analytic>
	<monogr>
		<title level="j">The New England journal of medicine</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="1543" to="1554" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. The European respiratory journal</title>
		<author>
			<persName><forename type="first">R</forename><surname>Casaburi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Mahler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wanner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>San</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Zuwallack</surname></persName>
		</author>
		<idno type="PMID">11866001</idno>
		<imprint>
			<date type="published" when="2002">2002</date>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="217" to="224" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Keam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Keating</surname></persName>
		</author>
		<idno type="PMID">15350163</idno>
	</analytic>
	<monogr>
		<title level="j">Treatments in respiratory medicine</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="247" to="268" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Testing two different doses of tiotropium Respimat(R) in cystic fibrosis: phase 2 randomized trial results</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bradley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Koker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moroni-Zentgraf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ratjen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Geller</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0106195</idno>
		<idno type="PMID">25188297</idno>
	</analytic>
	<monogr>
		<title level="j">PloS one</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">e106195</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Tiotropium Respimat(R) in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials</title>
		<author>
			<persName><forename type="first">F</forename><surname>Ratjen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Koker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Geller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Langellier-Cocteaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Maulf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kattenbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Farrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Rosenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Accurso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Castellani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Cutting</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jpeds.2008.05.005</idno>
		<idno type="PMID">18639722</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of pediatrics</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S4" to="S14" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Report from the EuroCareCF Working Group on outcome parameters in clinical trials</title>
		<author>
			<persName><forename type="first">D</forename><surname>Bilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Canny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Conway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dumcius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hjelte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Proesmans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="S79" to="81" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Pulmonary exacerbation: towards a definition for use in clinical trials. Suppl</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Year-to-year changes in lung function in individuals with cystic fibrosis</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">G</forename><surname>Liou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Elkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Pasta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Konstan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Morgan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="250" to="256" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Konstan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Wagener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Pasta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Millar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yegin</surname></persName>
		</author>
		<idno type="DOI">10.1002/ppul.21388</idno>
		<idno type="PMID">21438174</idno>
	</analytic>
	<monogr>
		<title level="j">Pediatric pulmonology</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="545" to="553" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Loss of fat-free mass over four years in adult cystic fibrosis is associated with high serum interleukin-6 levels but not tumour necrosis factor-alpha</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">B</forename><surname>Nyulasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kotsimbos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Wilson</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.clnu.2013.04.012</idno>
		<idno type="PMID">23664115</idno>
	</analytic>
	<monogr>
		<title level="j">Clinical nutrition</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="150" to="155" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">The two-sample t test versus Satterthwaite&apos;s approximate F test</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">K</forename><surname>Moser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Watts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Communications in Statistics A-Theory and Methods</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Risk factors for rate of decline in FEV1 in adults with cystic fibrosis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Konstan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Wagener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Vandevanter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Pasta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yegin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rasouliyan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="405" to="411" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m" type="main">Treatment of pulmonary exacerbations in cystic fibrosis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bhatt</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2013">2013</date>
			<publisher>European Respiratory Society</publisher>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="205" to="216" />
		</imprint>
	</monogr>
	<note>European respiratory review: an official journal of the</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Safety, tolerability, and plasma exposure of tiotropium Respimat(R) in children and adults with cystic fibrosis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Konstan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moroni-Zentgraf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Koker</surname></persName>
		</author>
		<idno type="DOI">10.1089/jamp.2013.1115</idno>
		<idno type="PMID">25380193</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of aerosol medicine and pulmonary drug delivery</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="137" to="144" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title level="m" type="main">How the airway smooth muscle in cystic fibrosis reacts in proinflammatory conditions: implications for airway hyper-responsiveness and asthma in cystic fibrosis. The Lancet Respiratory medicine</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mccuaig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Martin</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2213-2600(12)70058-9</idno>
		<idno type="PMID">24429094</idno>
		<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="137" to="147" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Muscarinic receptor signaling in the pathophysiology of asthma and COPD</title>
		<author>
			<persName><forename type="first">R</forename><surname>Gosens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zaagsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Meurs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Halayko</surname></persName>
		</author>
		<idno type="PMID">16684353</idno>
	</analytic>
	<monogr>
		<title level="j">Respiratory research</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">73</biblScope>
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<title level="m" type="main">Pharmacological treatment of chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease</title>
		<author>
			<persName><forename type="first">P</forename><surname>Montuschi</surname></persName>
		</author>
		<idno type="PMID">18044097</idno>
		<imprint>
			<date type="published" when="2006">2006</date>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="409" to="423" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<monogr>
		<title level="m" type="main">Tiotropium reduction of lung inflammation in a model of chronic gastro-oesophageal reflux. The European respiratory journal</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Devillier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Kuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1183/09031936.00139909</idno>
		<idno type="PMID">19926736</idno>
		<imprint>
			<date type="published" when="2010">2010</date>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1370" to="1376" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Effect of tiotropium bromide on airway remodeling in a chronic asthma model. Annals of allergy, asthma &amp; immunology: official publication of the American College of Allergy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Rhee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Asthma, &amp; Immunology</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="29" to="35" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Cystic fibrosis airway epithelium remodelling: involvement of inflammation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Adam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Roux-Delrieu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Luczka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bonnomet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lesage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Merol</surname></persName>
		</author>
		<idno type="DOI">10.1002/path.4471</idno>
		<idno type="PMID">25348090</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of pathology</title>
		<imprint>
			<biblScope unit="volume">235</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="408" to="419" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
